ASH 2021

I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

Medical Materials

Agenda

Coming soon

09:30 AM

Duration 10mins B207-B208

Cost-Effectiveness Analysis of Venetoclax Plus Azacitidine vs. Azacitidine in Newly Diagnosed Adult Patients With Acute Myeloid Leukemia Who Are Ineligible For Intensive Chemotherapy From a United States Payer Perspective

Pratz K, Chai X, Xie J, Yin L, Nie X, Montez M, Iantuono E, Downs L, Ma E

Duration 10mins Hall C1

Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination With Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Kumar SK, Harrison SJ, Cavo M, de La Rubia J, Popat R, Gasparetto C, Hungria V, Salwender H, Suzuki K, Kim I, Onishi M, Ku G, Pothacamury R, Sehgal V, Masud A, Ross JA, Dobkowska E, Moreau P

Hematology - Oncology | Multiple Myeloma

12:00 PM

Duration 10mins Hall C1

Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma: updated results from an ongoing Phase I study

Trudel S, Cohen AD, Krishnan A, Fonseca R, Spencer A, Berdeja JG, Lesokhin A, Forsberg PA, Laubach JP, Costa LJ, Rodriguez-Otero P, Kaedbey R, Richter J, Mateos M-V, Thomas SK, Wong C, Li M, Choeurng V, Vaze A, Samineni D, Sumiyoshi T, Cooper J, Harrison S

Hematology - Oncology | Multiple Myeloma

Duration 10mins Thomas Murphy Ballroom 1-2

Glofitamab as Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Morschhauser F, Carlo-Stella C, Dickinson M, Phillips T, Houot R, Offner F, Haioun C, Corradini P, Hutchings M, Sureda A, Martinez-Lopez J, Wróbel T, Wu S-J, Lundberg L, Mulvihill E, Perez-Callejo D, Relf J, Panchal A, Humphrey K, Bachy E

Hematology - Oncology | Non Hodgkin Lymphoma - Follicular Lymphoma

Duration 10mins Thomas Murphy Ballroom 1-2

Glofitamab Step-Up Dosing Induces High Response Rates in Pts With R/R MCL, Most of Whom Had Failed Prior BTKi Therapy

Phillips T, Dickinson M, Morschhauser F, Bachy E, Crump M, Trnĕný M, Bartlett N, Zaucha J, Humphrey K, Perez-Callejo D, Lundberg L, Relf J, Filezac de L’Etang A, Carlile D, Clark E, Carlo-Stella C

Hematology - Oncology | Non Hodgkin Lymphoma - Mantle Cell Lymphoma

Duration 10mins Thomas Murphy Ballroom 1-2

Mosunetuzumab in Combination With Lenalidomide has a Manageable Safety Profile and Encouraging Activity in Patients With Relapsed/Refractory Follicular Lymphoma: Initial Results From a Phase Ib Study

Morschhauser F, Bishton M, Eyre TA, Bachy E, Cartron G, Ysebaert L, Bobillo S, Gutierrez NC, Budde LE, Fox CP, Knapp A, Yaqub M, Wei MC, O'Hear C, Li H, Purev E, Townsend W

Hematology - Oncology | Non Hodgkin Lymphoma - Follicular Lymphoma

Duration 10mins Thomas Murphy Ballroom 1-2

Mosunetuzumab Monotherapy is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) who have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil L, Wei MC, Yin S, Doral MY, Li C-C, Huang H, Negricea R, Penuel E, O'Hear C, Bartlett NL

Hematology - Oncology | Non Hodgkin Lymphoma - Follicular Lymphoma

02:00 PM

Duration 10mins B207-B208

Molecular Responses are Observed Across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax plus Azacitidine

Garcia JS, Wei AH, Jacoby MA, Fong CY, Borate U, Baer MR, Cunningham I, Odenike O, Jurcic JG, Nowak D, Peterlin P, Platzbecker U, Dunshee D, Zhou Y, Hoffman D, Sun Y, Popovic R, Ainsworth B, Naqvi K, Kye S, Hogdal L, Garcia-Manero G

Hematology - Oncology | Leukemia & Lymphoma

Duration 10mins Sidney Marcus Auditorium

Outcomes in Patients with Poor-risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Azacitidine

Pollyea DA, Pratz KW, Wei AH, Pullarkat V, Jonas BA, Recher C, Babu S, Schuh AC, Dail M, Sun Y, Potluri J, Chyla B, DiNardo CD

Hematology - Oncology | Acute Myeloid Leukemia

09:30 AM

Duration 10mins C211-C213

Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study

Negrier C, Mahlangu J, Lehle M, Chowdary P, Catalani O, Jimenez-Yuste V, Beckermann BM, Schmitt C, Hermans C, Ventriglia G, Windyga J, Kiialainen A, d'Oiron R, Moorehead P, Teodoro V, Shapiro AD, Oldenburg J

Hematology - Oncology | Hemophilia A

Duration 10mins C211-C213

Emicizumab Outcomes in Hemophilia A Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry

Poon M-C, Lee A, Germini F, Keepanasseril A, Ibrahim Q, Nissen F, Sanabria F, Santos M, Iserman E, Matino D, Iorio A

Hematology - Oncology | Hemophilia A

Duration 10mins C211-C213

Surgical Experience from the Phase IIIb STASEY Trial of Emicizumab Prophylaxis in Persons with Hemophilia A with FVIII Inhibitors: Final Analysis

Castaman G, Windgya J, Alzahrani H, Robson S, Sanabria F, Howard M, Jimenez-Yuste V

Hematology - Oncology | Hemophilia A

04:30 PM

Duration 10mins Thomas Murphy Ballroom 1-2

Glofitamab in Combination with Polatuzumab Vedotin: Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Hutchings M, Sureda A, Terol MJ, Bosch F, Corradini P, Stauffer Larsen T, Rueda Dominguez A, Panchal A, Bottos A, Wang Y, Filézac de L’Etang A, Tandon M, Sellam G, Gritti G

Hematology - Oncology | Non Hodgkin Lymphoma - Diffuse Large B-Cell Lymphoma

Duration 10mins Thomas Murphy Ballroom 3-5

Mosunetuzumab Plus Polatuzumab Vedotin has Promising Efficacy and a Favorable Safety Profile in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma: Updated Results from a Phase Ib/II Study

Budde LE, Olszewski A, Assouline S, Kamdar M, Diefenbach C, Ghosh N, Lossos IS, Mehta A, Sabry W, Dorritie K, Pham S, Xu J, Huw L-Y, To I, Oki Y, O'Hear C, Chavez J

Hematology - Oncology | Non Hodgkin Lymphoma

Duration 10mins B211-B212

Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome

Zeidan AM, Borate U, Pollyea DA, Brunner AM, Roncolato F, Garcia JS, Filshie RJ, Odenike O, Watson A-M, Bajel A, Naqvi K, Zha J, Hogdal L, Zhou Y, Hoffman D, Kye S, Garcia-Manero G

Hematology - Oncology | Leukemia & Lymphoma

10:30 AM

Duration 10mins B312-B314

A Novel Methodology for Building Longitudinal, Patient-Centric Real World Datasets in Hemophilia A

Skinner MW, Hanson G, Xu T, Ofori-Asenso R, Ko RH, Cibelli E, Nissen F, Witkop M, Sanabria F, Shapiro AD

Hematology - Oncology | Hemophilia A

02:45 PM

Duration 10mins B308-B309

Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 Mutation in Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Siddani S, Wang J, Chyla B, Lee P, Altman JK

Hematology - Oncology | Acute Myeloid Leukemia

09:00 AM

Duration 10mins Hall C2-C3

The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers C, Salles G

Hematology - Oncology | Diffuse Large B-Cell Lymphoma

I am a healthcare professional

Notice

Cookies

External site

ASH 2021